Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

JPMorgan notes that shares of Oric Pharmaceuticals (ORIC) have come under pressure late yesterday into early today following the release of the ...

Following receipt of increasing peanut oral immunotherapy, or home-measured peanut butter, desensitization to peanut protein ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

Q3 2024 Earnings Call Transcript February 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is $0.23, expectations were $-0.24. Operator: Ladies and gentlemen, thank you for ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...

As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...

Deutsche Bank (ETR:DBKGn) initiated coverage on shares of Biohaven Pharmaceutical (TADAWUL:2070) Holding (NYSE:BHVN) with a Buy rating and a price target of $65.00. The firm's analysts cited the ...

Stephanie Lee Griffin; Chief Operating Officer; Roivant Sciences Ltd. Matt Gline; Chief Executive Officer, Director; Roivant Sciences Ltd. Dave Risinger; Analyst; Le ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...